Motor analysis predicts progression in HIV-associated brain disease

Area of Science:

• Neurology
• Infectious Diseases
• Virology

Background:

• Human Immunodeficiency Virus (HIV) can affect the central nervous system (CNS).
• Motor deficits may indicate early neurological involvement in HIV.
• Understanding disease progression and treatment effects is crucial for patient outcomes.

Purpose of the Study:

• To investigate the relationship between electrophysiologically detectable motor impairment and subsequent CNS involvement in HIV-positive individuals.
• To evaluate the clinical and electrophysiological outcomes of HIV patients with varying degrees of motor impairment and treatment statuses.
• To assess the impact of AZT (azidothymidine) treatment on motor function and neurological complications.

Main Methods:

• A 2-year follow-up study of 100 HIV-positive individuals without initial CNS deficits.
• Clinical examinations and a motor test battery administered every 3 months.
• Annual magnetic resonance tomography (MRT) scans.
• Patients categorized into three groups: no motor impairment, detectable motor impairment without medication, and motor impairment with AZT treatment.

Main Results:

• Group A (no motor impairment) showed slight deterioration but had the best outcomes.
• Group B (motor impairment, no medication) deteriorated significantly in clinical and electrophysiological tests.
• Group C (motor impairment, AZT treatment) showed improvement in early stages (CDC II-III) but high mortality and dementia in advanced stages (CDC IVA-D).
• Late initiation of virostatic treatment did not improve clinical outcomes.

Conclusions:

• Early detectable motor impairment is a predictor of future cerebral involvement in HIV/AIDS.
• Timely intervention with AZT may benefit patients in early disease stages.
• Advanced HIV disease stages are associated with poor outcomes, including cerebral complications and dementia, even with treatment.